Latanoprost acid
|
|
|
- CAS-Nr.
- 41639-83-2
- Englisch Name:
- Latanoprost acid
- Synonyma:
- (5Z)-;LAT-FA;LT-Acid;PHXA 85;LATANOPROST ACID;latanoprostfreeaci;LATANOPROST (FREE ACID);LATANOPROSTACID;PHXA 85;Latanoprost Impurity 23;LT-ACID(LATANOPROST ACID)
- CBNumber:
- CB4208385
- Summenformel:
- C23H34O5
- Molgewicht:
- 390.51
- MOL-Datei:
- 41639-83-2.mol
|
Latanoprost acid Eigenschaften
- Siedepunkt:
- 609.1±50.0 °C(Predicted)
- Dichte
- 1.159±0.06 g/cm3(Predicted)
- storage temp.
- -20°C
- L?slichkeit
- DMSO: freely soluble
- pka
- 4.76±0.10(Predicted)
- Aggregatzustand
- Oil
- Farbe
- pale yellow, oil
- Stabilit?t:
- Hygroscopic
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| WGK Germany |
3 |
|
|
| HS Code |
2937500000 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P302+P352 |
BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Latanoprost acid Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Latanoprost is an F-
series prostaglandin (PG) analog which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester, a prodrug form which is converted to latanoprost (free acid) by endogenous esterase enzymes. The free acid form is 200 times more potent than latanoprost as an FP receptor ligand for the human recombinant FP receptor. Latanoprost is the isopropyl ester of a PGF
2α analog containing an aromatic group (17-
phenyl) in the ω-
chain. Lat-
FA is the corresponding carboxylic acid of this analog. Lat-
FA is a potent FP receptor agonist with an EC
50 of 3.6 nM for human FP receptors, which is twice the potency of PGF
2α. The efficacy of PG analog esters for the treatment of glaucoma correlates closely with the FP receptor binding affinity of the free acid. However, Lat-
FA is more irritating and less effective than the prodrug latanoprost when applied directly to the eyes of human glaucoma patients.
Chemische Eigenschaften
Pale Yellow Oil
Definition
ChEBI: A prostaglandin Falpha that is an analogue of prostaglandin F2alpha in which the pentyl group has been replaced by 2-phenylethyl and where the the 13,14-double bond has undergone f
rmal hydrogenation. Its isopropyl ester prodrug, latanoprost, is used in the treatment of open-angle glaucoma and ocular hypertension.
Latanoprost acid Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Latanoprost acid Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 121)Lieferanten
41639-83-2()Verwandte Suche:
- LATANOPROST (FREE ACID)
- LAT-FA
- 17-PHENYL-13,14-DIHYDRO TRINOR PROSTAGLANDIN F2ALPHA
- (5Z,9ALPHA,11ALPHA,15R)-9,11,15-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROST-5-EN-1-OIC ACID
- 9ALPHA, 11ALPHA, 15R-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROST-5Z-EN-1-OIC ACID
- PHXA 85
- PhXA 85, (5Z,9α,11α,15R)-9,11,15-Trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oic acid
- Latanoprost acid,(5Z,9α,11α,15R)-9,11,15-Trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oic acid, PhXA 85
- LT-ACID(LATANOPROST ACID)
- LT-Acid
- (5z,9α,11α,15r)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oic acid
- (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoic acid
- LATANOPROST ACID
- (5Z)-
- Latanoprost Related CoMpound E
- Latanoprost Related Compound E (25 mg) ((Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}-5-heptenoic acid)
- (Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}-5-heptenoic acid
- LT-Acid(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoic acid
- LATANOPROSTACID;PHXA 85
- (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid
- Latanoprost Impurity 8（Latanoprost Acid）
- Latanoprost Acid/(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoic acid
- 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, (5Z)-
- latanoprostfreeaci
- Latanoprost Related Compound E ((Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl (1357533)
- Latanoprost Impurity 23
- Latanoprost EP Impurity H
- Latanoprost EP Impurity H (Latanoprost USP Related Compound E)
- Latanoprost Acid / Latanoprost Related Compound-E
- Latanoprost acid (related compound E)
- 41639-83-2
- 7130209-82-4
- C26H40O5
- C23H35O5
- Aromatics, Chiral Reagents, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
- Aromatics
- Chiral Reagents
- Intermediates & Fine Chemicals
- Metabolites & Impurities
- Pharmaceuticals
